BIC/LEN FDC

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

HIV-1-infection

Phase 2

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

Active, not recruitingNCT05502341

Gilead SciencesHIV-1-infection

Start: 2022-08-16End: 2028-07-31Updated: 2025-10-14

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

RecruitingNCT06532656

Gilead SciencesHIV-1-infection

Start: 2024-11-20End: 2028-08-31Target: 75Updated: 2026-01-12

Related Papers

The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study.

2025-11-28

Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)

Clinical Infectious Diseases2024-10-304 citations